Almonds are a good source of beneficial compounds. This study will investigate if eating almonds everyday for 12 weeks can affect gut health and inflammation in persons with metabolic syndrome. Investigators will measure changes in metabolism, heart health, and the levels of vitamins and other compounds from almonds.
Metabolic Syndrome (MetS) affects over a billion people world-wide. MetS progression and further health complications are driven by chronic inflammation. Major causes of inflammation in MetS are gut barrier breakdown and the absorption of harmful bacteria. What causes the gut barrier breakdown is not clear, but a poor diet, especially low micronutrient intakes like vitamin E, is implicated by propagating a vicious cycle that promotes oxidative stress, inflammation and further gut barrier damage. This study will assess the impact of daily consumption of 2 ounces of almonds for 12 weeks on gut health, markers of inflammation and cardiometabolic health, and micronutrient status in persons with MetS.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
80
Oregon State University
Corvallis, Oregon, United States
Gut permeability and health: Serum endotoxin
Change from baseline at week 4: Marker of gut barrier function and health, serum endotoxin
Time frame: 0 and 4 weeks
Gut permeability and health: Short chain fatty acids
Change from baseline at week 4: Markers of gut barrier function and health fecal short chain fatty acids profiles
Time frame: 0 and 4 weeks
Gut permeability and health: Inflammatory biomarkers
Change from baseline at week 4: Gut inflammatory biomarkers calprotectin and myeloperoxidase
Time frame: 0 and 4 weeks
Biomarkers of inflammation
Change from baseline at week 4: Plasma inflammatory markers (ex. TNF and IL-6)
Time frame: 0 and 4 weeks
Oxidative stress status: malondialdehyde
Change from baseline at week 4: Plasma malondialdehyde
Time frame: 0 and 4 weeks
Oxidative stress status: isoprostanes
Change from baseline at week 4: Urinary isoprostanes
Time frame: 0 and 4 weeks
Cardiometabolic health
Change from baseline at week 12: Total cholesterol, LDL, HDL, and triglycerides
Time frame: 0 and 12 weeks
Vitamin E status
Change from baseline at week 4 and week 12: Plasma α-tocopherols
Time frame: 0, 4 and 12 weeks
Vitamin E status: Urinary catabolite
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Change from baseline at week 4 and week 12: Urinary vitamin E catabolite (α-CEHC)
Time frame: 0, 4 and 12 weeks
Blood pressure
Change from baseline at week 4 and week 12: Systolic, and diastolic blood pressure
Time frame: 0, 4 and 12 weeks
Weight
Change from baseline at week 4 and week 12: Weight
Time frame: 0, 4 and 12 weeks
BMI
Change from baseline at week 4 and week 12: BMI (weight and height will be combined to report BMI in kg/m\^2)
Time frame: 0, 4 and 12 weeks
Waist circumference
Change from baseline at week 4 and week 12: Waist circumference
Time frame: 0, 4 and 12 weeks
Glycemic control: glucose
Change from baseline at week 12: Fasting blood glucose
Time frame: 0 and 12 weeks
Glycemic control: Insulin
Change from baseline at week 12: Insulin
Time frame: 0 and 12 weeks
Glycemic control: HOMA-IR
Change from baseline at week 12: HOMA-IR
Time frame: 0 and 12 weeks
Other almond-based bioactives (polyphenol levels)
Change from baseline at week 12: Urinary metabolites of flavonoids like (+)-catechin, (-)-epicatechin and naringenin
Time frame: 0 and 12 weeks
Mineral status
Change from baseline at week 12: Plasma magnesium, calcium, iron, zinc, and copper (microgram/mL)
Time frame: 0 and 12 weeks